EIF2A and Alzheimer disease: Importantly, since the significant increase of the phosphorylation level of eIF2α was observed in APOE4 cerebral organoids, our results suggest that ISR inhibition can be a potential therapeutic target for APOE4-mediated pathogenesis in AD.